PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng Y, Wang Y, Zhou C, Mei W, Zeng C. · 2022
Read PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? by Peng Y, Wang Y, Zhou C, Mei W, Zeng C. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8987494.txt.
Description
Peng and co-authors ask whether drugs against the PI3K/Akt/mTOR pathway are truly making headway in cancer. This growth pathway switches on abnormally in many tumors. It feeds cell division and blood vessel growth. It also helps tumors resist chemotherapy. The review catalogs the pathway's cancer alterations first. Gene changes in its members recur across tumor types. Hallmarks tied to the pathway follow. Cell death, cleanup, and shape change all appear.
Inhibitor research gets the closing focus. Many compounds have entered trials over the years. Results so far are mixed, the authors imply. Understanding the pathway in depth should guide choices. Which patients, which partners, which timing remain open. The authors aim the review at clinical decision makers. The title's question is answered cautiously. Headway exists, but it is hard won.
Catalog record
| CREATOR | Peng Y, Wang Y, Zhou C, Mei W, Zeng C. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 85 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |